OR WAIT null SECS
February 08, 2022
With new COVID-19 infections declining, the agency is resuming domestic inspections of drug manufacturing facilities.
MacroGenics will use Synaffix’s technology to investigate next-generation ADCs.
February 07, 2022
The acquisition will include Rewrite’s DNA writing platform, expanding Intellia’s genome editing tools.
The agency approved Roche’s Vabysmo to treat neovascular or “wet” age-related macular degeneration and diabetic macular edema.
Bio-Rad’s four new antibodies will develop highly selective and sensitive assays for bioanalysis and drug monitoring of pertuzumab and its biosimilars.
Gandeeva raisded $40 million to advance its AI-driven cryo-EM platform, with which it will develop new therapeutics based on the precise imaging of protein–drug interactions.
A range of political issues have impacted FDA initiatives vital to the agency’s effectiveness and stature, both at home and on the important global stage.
February 04, 2022
Domainex is collaborating with Parkinson’s UK for the development of small-molecule therapies targeting the neuroinflammation that is associated with Parkinson’s disease.
ABPI has responded to the publication of a white paper on ‘Levelling Up’ by the government of the United Kingdom.
Zetta Genomics has raised £2.5 million ($3.4 million) in new seed funding.
